BioVaxys Technology Corp. is in non-binding talks to acquire an immunotherapeutics IP portfolio in oncology and immunology from a biotech company, now held by a secured creditor. No formal agreement is established, cautioning investors about share trading. Uncertainty surrounds the deal’s completion. Shareholders are urged to await further updates as no certainty exists regarding agreement terms or finalizing the transaction.
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that it is in non-binding discussions to acquire an immunotherapeutics intellectual property portfolio of discovery, preclinical and clinical development stage assets in oncology and other immunological fields formerly owned by an unnamed biotechnology company and now held by the secured creditor. At this time, no formal agreement is in place.
Investors are advised to use caution in trading the Company’s shares while non-binding discussions are underway. There is no certainty and there can be no assurance that the parties will reach agreement on terms or will complete any transaction. We advise shareholders to await further developments.
Source: Bio Space
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
